Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST
2024-513581-19-00Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in carotid atheroma (CAS) and atherosclerosis comparing Omalizumab with Placebo (2 arms). Primary endpoint: Mast cell activation in carotid plaque. Started Aug 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
carotid atheroma (CAS)atherosclerosis
Beyond the preview
Go deeper on 2024-513581-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513581-19-00.